Eli Lilly Gets $1.29 Billion U.S. Order for Covid-19 Cocktail
November 02 2021 - 7:51AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. on Tuesday said the U.S. government has
placed a $1.29 billion order for another 614,000 doses of its
Covid-19 drug cocktail of bamlanivimab with etesevimab.
The Indianapolis drugmaker said it would supply at least 400,000
doses of the antibody therapy, which is authorized for emergency
use for the treatment of mild to moderate Covid-19 or for
post-exposure prevention of Covid-19 in certain individuals, by the
end of the year, with the remainder delivered by the end of
January.
Eli Lilly, which last week forecast full-year adjusted earnings
of $7.95 to $8.05 a share on revenue of $27.2 billion to $27.6
billion, said the new order adds $840 million of revenue and about
25 cents of per-share earnings to its 2021 guidance.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 02, 2021 07:36 ET (11:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Sep 2023 to Sep 2024